Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D0DH
|
|||
| Drug Name |
TLPLDC
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [2], [3] | ||
| Company |
Cancer InsightSan Antonio, TX Elios Therapeutics Austin, TX
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02301611) Phase IIB TL + YCWP + DC in Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.